[4-[2-[[2-(Methylamino)-2-oxoethyl]amino]ethylamino]-4-oxobutyl]-triphenylphosphanium;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-[2-[[2-(Methylamino)-2-oxoethyl]amino]ethylamino]-4-oxobutyl]-triphenylphosphanium;chloride
• 英文别名: [4-[2-[[2-(methylamino)-2-oxoethyl]amino]ethylamino]-4-oxobutyl]-triphenylphosphanium;chloride
• 化学式: C27H33ClN3O2P
• 分子量: 498.0
• InChiKey: YPYFQUFSWCTDQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.78
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  70.2
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Compositions and Methods for Treating Conditions that Affect Epidermis
  申请人：GENCIA CORPORATION

  公开号：US20160022709A1

  公开（公告）日：2016-01-28

  The present invention relates to the compositions and methods for treating or alleviating conditions that affect the epidermis (e.g., wrinkles, sun damaged skin, symptoms of aged skin, or the like).

  本发明涉及用于治疗或缓解影响表皮的状况（例如皱纹、受阳光损伤的皮肤、老化皮肤的症状等）的组合物和方法。
• PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF
  申请人：ALS Mountain Llc

  公开号：EP2983473A2

  公开（公告）日：2016-02-17
• Compositions and Methods for Treating Conditions That Affect Epidermis
  申请人：Gencia Corporation

  公开号：US20180000846A1

  公开（公告）日：2018-01-04

  The present invention relates to the compositions and methods for treating or alleviating conditions that affect the epidermis (e.g., wrinkles, sun damaged skin, symptoms of aged skin, or the like).
• US9707244B2
  申请人：——

  公开号：US9707244B2

  公开（公告）日：2017-07-18
• [EN] PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT UN ACTIVATEUR D'AMPK ET UN AGENT SÉROTONINERGIQUE ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
  申请人：ALS MOUNTAIN LLC

  公开号：WO2014144130A2

  公开（公告）日：2014-09-18

  The present invention is based on the unexpected discovery that a combination of certain known drugs exhibits synergistic effects in treating metabolic syndrome and various other diseases. In particular, the invention comprises a pharmaceutical composition comprising: (1) a therapeutically effective quantity of a first agent that is an AMPK activator; and (2) a therapeutically effective quantity of a second agent that possesses or maintains serotonin activity. A preferred composition comprises metformin hydrochloride and melatonin. The invention further comprises methods for the use of these compositions for the treatment of metabolic syndrome, hyperproliferative diseases including cancer, and other diseases and conditions.